Click here for Logical Analysis ReportOp-ed:
From our analysis, we found the following most relevant:The British-Swedish pharmaceutical giant is aiming to produce 2 billion doses of the vaccine, with a view to roll 400 million doses out to the U.S. by October.
AstraZeneca's vaccine has also received multimillion dollar investments from the U.K. government and a $843 million payment from some EU countries, who have secured access to the vaccine should it prove to be effective.
Meanwhile, the Canadian government's National Research Council has signed a deal with China's CanSino Biologics to manufacture its vaccine for clinical trials in Canada this summerExisting international institutions and agreements will struggle to minimize this 'vaccine nationalism.'"
The research group argued that some governments were already attempting to seize first access through large-scale investments.
"In the U.S., the Biomedical Advanced Research Development Authority (BARDA) has been spreading its investments across a number of vaccine candidates in an effort to reduce the financial risks for pharmaceutical firms and lock in priority access to a successful vaccine," the note's authors said.
BARDA has financial interests in Moderna's candidate vaccine and has invested in early research being conducted by French firm Sanofi and Britain's GlaxoSmithKline.
In May, the U.S. also invested $1 billion in AstraZeneca's potential vaccine, which is being developed by scientists at the University of OxfordWe're all in the same game, so it will happen."
Likening the vaccine development landscape to the space race of the 20th century, Rountree warned that vast government investments would not miraculously pave the way to an effective vaccine.
"Politicians can put aggressive timelines in, and it lends itself to putting a man on the moon," he said